RGNT.US Regentis Biomaterials Ltd.
- Market cap
- USD 8.36M
- P/E
- -
- P/B
- 1.12x
- ROE
- -287.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is RGNT.US undervalued?
Graham numberThe Graham number of Regentis Biomaterials Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Regentis Biomaterials Ltd. fundamental analysis
No fundamental analysis for Regentis Biomaterials Ltd. yet.
Regentis Biomaterials Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorpo…
Full company profileRegentis Biomaterials Ltd. financial statements
Regentis Biomaterials Ltd. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.41M | -1.93M | 932K | -8.62M |
| EBITDA | -1.45M | -3.96M | 4.97M | -13.3M |
| Net Income | -1.45M | -4.13M | 4.80M | -13.6M |
| EPS | -0.29 | -0.84 | 0.93 | -2.64 |
| Balance Sheet | ||||
| Total Assets | 1.72M | 360K | 482K | 7.62M |
| Total Liabilities | 43.8M | 46.3M | 41.6M | 2.87M |
| Shareholders' Equity | -42.1M | -45.9M | -41.1M | 4.74M |
| Cash & Short-term Investments | 1.24M | 345K | 229K | 7.38M |
| Cash Flow | ||||
| Operating Cash Flow | -1.50M | -1.22M | -641K | -1.38M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.50M | -1.22M | -641K | -1.38M |
| Ratios | ||||
| ROE | - | - | - | -287.7% |
| ROA | -84.4% | -1,147.8% | 996.1% | -179.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Regentis Biomaterials Ltd. dividends
Regentis Biomaterials Ltd. has not paid dividends in the last 4 fiscal years.
Who owns Regentis Biomaterials Ltd.
- Insiders 14.05%
- Institutions 25.85%
- Public & others 60.11%
- Shares outstanding 7.02M
- Free float 4.26M
Regentis Biomaterials Ltd. company profile
- Company name
- Regentis Biomaterials Ltd.
- Ticker
- RGNT.US
- ISIN
- IL0012190968
- Exchange
- USA Stocks
- Listed since
- Dec 4, 2025
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 60, Medinat Hayehudim, Herzliya, Israel, 4676652
- Phone
- 972 9 960 1917
- Website
- regentis.co.il
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Regentis Biomaterials Ltd. management
5- Dr. Ehud Geller Ph.D.CEO & Executive Chairman
- Mr. Arie Gordashnikov CPAChief Accounting Officer · born 1984
- Dr. Dror Seliktar Ph.D.Co-Founder & Chief Scientific Officer
- Mr. Ori GonCFO & Chief Business Officer · born 1982
- Dr. Galit Reske Ph.D.Chief Medical Officer · born 1972